Update on negotiations with NCI regarding OptiMAL

AI SummaryClose X

Fusion Antibodies plc has announced that the National Cancer Institute (NCI) has expressed interest in continuing to use its OptiMAL® platform for antibody discovery, following a successful validation project. Negotiations are underway for an extended collaboration agreement to screen several new targets, with discussions expected to continue into early 2026. While formal approval processes at the US National Institutes of Health are anticipated to take several more months, there is no certainty of reaching an agreement or its final terms. The NCI's continued interest is seen as a strong validation of the OptiMAL® platform.

Disclaimer*

UK 100

Latest directors dealings